Pharmaceuticals
ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer
SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data onits Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, "BFv") in locally...
2026-10-19 10:00
4160
UEG Week 2026: Antibiotic use from childhood linked to higher odds of IBS in young adulthood
BARCELONA, Spain, Oct. 19, 2026 /PRNewswire/ -- Antibiotic use from childhood through early adulthood is associated with higher odds of irritable bowel syndrome (IBS) at age 24, with the odds increasing as the number of antibiotic prescriptions rose, according to a new study presented today atUEG...
2026-10-19 06:01
1925
Abu Dhabi Health Delegation Concludes Inaugural Visit to China, Opening New Pathways to Advance AI, Precision Medicine and Next-Gen Therapies
ABU DHABI, UAE, Oct. 18, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has concluded its inaugural health and life sciences mission to China, advancing priority areas of collaboration designed to accelerate the translation ...
2026-10-18 01:54
6092
Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
NEW TAIPEI CITY, Oct. 16, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it plans to establish a po...
2026-10-16 08:00
8187
Pope Leo XIV's Lung Cancer Diagnosis Puts Spotlight on Hope and Advances in Treatment
IASLC highlights global collaboration, advancing lung cancer care and bringing new hope to patients and families. DENVER, Oct. 15, 2026 /PRNewswire/ -- Pope Leo XIV's diagnosis of lung adenocarcinoma has brought global attention to a disease that affects millions of individuals and families acro...
2026-10-15 23:30
1982
Brii Biosciences Unveils BRiSC™, an siRNA Therapeutics Discovery Platform
Proprietary BRiSC™ platform to advance the discovery and development of next-generation dual-targeting siRNA medicines Initial focus on prevalent metabolic dysfunctions where complex disease biology and overlapping comorbidities will benefit from coordinated modulation of multiple therapeutic ta...
2026-10-15 19:30
2050
Opella: New study demonstrates successful cough treatment extends beyond symptom relief
PARIS, Oct. 15, 2026 /PRNewswire/ -- A new real-world study from Opella, the maker of Mucosolvan and Bisolvon, provides pharmacists with compelling evidence that the success of a cough treatment should be measured by its impact on a patient's overall well-being, alongside traditional symptomatic ...
2026-10-15 07:01
2050
Tsingke Customer Quality Audit Highlights Manufacturing Systems and Quality Controls
BEIJING, Oct. 14, 2026 /PRNewswire/ -- As synthetic biology expands into new applications, standardized manufacturing processes, reliable production data, and robust quality management systems are becoming increasingly important. Tsingke recently hosted an on-site customer quality audit conducted...
2026-10-14 22:19
1645
Neurophet Honored with Two Awards at the BioSpectrum Asia Excellence Awards 2026
* Receives Awards for MedTech Innovation and AI-Driven Clinical Development; Only Korean Company Recognized in Two Categories * Recognized for its capabilities in AI-driven clinical support and ICL services, with plans to expand partnerships with global CROs SEOUL, South Korea, Oct. 14, 2026 /...
2026-10-14 21:00
2202
Lunit SCOPE Reveals HER2 Expression Differences Linked to Treatment Response Beyond Conventional Testing in Nature Medicine Study
AI-powered whole-slide analysis provides insights into treatment response beyond conventional HER2 classification SEOUL, South Korea, Oct. 14, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced findings from a study p...
2026-10-14 21:00
2556
Continuity Biosciences Awarded $9.6 Million Grant to Advance Ultra-Long-Acting Implant for HIV Prevention
Funding supports development of a subcutaneous implant designed to deliver HIV prevention medicine for multiple years from a single placement, advancing toward an IND submission and initiation of a first-in-human Phase 1 study BRADENTON, Fla. and SEATTLE, Oct. 14, 2026 /PRNewswire/ -- Continuity ...
2026-10-14 20:00
1995
Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in ...
2026-10-14 13:00
3002
Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026
BEIJING, Oct. 14, 2026 /PRNewswire/ -- Likang Life Sciences will serve as a sponsor and exhibitor at the Abu Dhabi Future Health Summit 2026, to be held October 20–22 at the ADNEC Centre in Abu Dhabi, the United Arab Emirates. Shannon Cheung, Co-Founder and Vice Chairman of Likang, will join a pa...
2026-10-14 10:25
2505
Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)
SD-101 (Zorblesia™) is the First Topical Therapy Developed to Treat Wounds and Lesions Across the Entire Skin Surface of All Epidermolysis Bullosa (EB) Subtypes This second consecutive nomination places our company and focus on Epidermolysis Bullosa among a select group of visionaries shaping th...
2026-10-14 04:20
2789
AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases
* Sustained Boost in AI-Driven R&D Productivity: ISM9546 marks Insilico Medicine's 35th preclinical candidate (PCC) nominated since 2021 and its 11th PCC within the first 10 months of 2026 alone, setting a new record for the company's annual pipeline output efficiency. * AI-Enabled Molecular ...
2026-10-13 21:00
4001
Ailux Appoints Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer
* Dr. Miller will lead the advancement of the company's AI-native biologics toward first-in-human trials, with initial clinical entry targeted for 2027 * He will also establish a U.S. clinical and research site to complement the company's research capabilities in Shanghai and the U.K. SHANGHAI...
2026-10-13 20:00
3031
Kelun-Biotech to Present Multiple Study Results at ESMO 2026
CHENGDU, China, Oct. 13, 2026 /PRNewswire/ -- The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) will present results from multiple clini...
2026-10-13 19:23
2783
Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2 Hiteck retains all rights in Greater China, where a Phase 1b study in severe neurotrophic keratitis...
2026-10-13 19:00
2868
Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases
SANTA BARBARA, Calif., Oct. 13, 2026 /PRNewswire/ -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary ext...
2026-10-13 15:00
6759
Fosun International Wins Five Awards at The Asset Corporate Sustainability Leadership Awards 2026, Upgraded to Platinum
HONG KONG, Oct. 13, 2026 /PRNewswire/ -- Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) today announced that it has been awarded the prestigious"Corporate Sustainability Leadership Awards 2026 – Platinum Award" by The Asset, a leading Asia-Pacific fi...
2026-10-13 12:46
8766
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
52348
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
51309
